How India Exports Tofacitinib to the World

As of March 2026, the FDA has not approved any generic versions of Xeljanz (tofacitinib). The original approvals for Xeljanz tablets were granted to Pfizer on November 6, 2012, for the 5 mg strength, and on May 30, 2018, for the 10 mg strength. Additionally, an oral solution formulation was approved on September 25, 2020. The absence of approved generic alternatives indicates that Indian exporters must navigate the New Drug Application (NDA) pathway for market entry into the U.S. This regulatory landscape underscores the competitive environment, with 119 active Indian exporters vying for market share.

In the European Union, tofacitinib has received marketing authorization from the European Medicines Agency (EMA) for the treatment of rheumatoid arthritis and other specified conditions. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has similarly approved tofacitinib for these indications. Manufacturers exporting to these regions must comply with the EU's Good Manufacturing Practice (GMP) standards, ensuring product quality and safety.

Tofacitinib is not listed on the World Health Organization's (WHO) Model List of Essential Medicines as of the 24th edition published in September 2025. Consequently, it has not undergone the WHO Prequalification process. However, tofacitinib is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), which standardize its quality and formulation.

In India, tofacitinib is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for tofacitinib, allowing market-driven pricing. For export purposes, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for pharmaceuticals, ensuring compliance with export regulations.

Tofacitinib's primary patents have expired, opening the market to generic competition. However, in the U.S., no generic versions have been approved by the FDA as of March 2026, maintaining Pfizer's market exclusivity. This exclusivity impacts Indian exporters aiming to enter the U.S. market.

In May 2025, the WHO updated its Model List of Essential Medicines, and tofacitinib was not included in the 24th edition. In July 2025, the EMA approved an additional indication for tofacitinib, expanding its therapeutic applications within the EU. In September 2025, the NPPA reviewed the pricing of various pharmaceuticals but did not impose a ceiling price on tofacitinib, allowing continued market-driven pricing. In November 2025, the CDSCO issued new guidelines for the export of pharmaceuticals, emphasizing the requirement for an NOC, impacting the export procedures for tofacitinib. In January 2026, the FDA reiterated that no generic versions of Xeljanz had been approved, maintaining Pfizer's market exclusivity in the U.S.

These developments highlight the dynamic regulatory environment affecting tofacitinib's global market presence and the strategic considerations for Indian exporters.

Tofacitinib, a Janus kinase (JAK) inhibitor used in the treatment of autoimmune diseases, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) is heavily reliant on Key Starting Materials (KSMs) sourced from China. This dependency is significant, as China controls approximately 70–80% of the global KSM supply and 60–70% of the global intermediate supply, making it a dominant player in the pharmaceutical raw material market.

The COVID-19 pandemic in 2022 highlighted the vulnerabilities of this supply chain. Lockdowns and stringent measures in China led to delays in customs clearances at major ports, causing shipment delays of 8–12 weeks for precursor chemicals essential for API production. These disruptions had a cascading effect, impacting formulation facilities in Europe and North America.

Our proprietary trade data from 2022 to 2026 indicates a high supplier concentration in the export of Tofacitinib from India. The top five exporters account for 89.2% of the total export value, with SUN PHARMACEUTICAL INDUSTRIES LIMITED alone contributing 74.6%. This concentration poses a significant single-source risk, as any operational or quality issues within these key suppliers could disrupt the global supply chain.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme aimed at boosting domestic API production and reducing reliance on imports. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, marking a step towards reducing import dependence.

Geopolitical tensions and shipping disruptions have further exacerbated supply chain vulnerabilities. The Red Sea and Strait of Hormuz are critical maritime routes for global trade, and any instability in these regions can lead to shipping delays and increased costs. Additionally, escalating tensions between the U.S. and China have raised concerns about potential trade restrictions, which could impact the availability of KSMs and APIs.

Regulatory bodies have acknowledged these challenges. In January 2025, the FDA issued guidance on notifying the agency of permanent discontinuances or interruptions in manufacturing that could lead to meaningful disruptions in the supply of medical devices. While this guidance primarily addresses medical devices, it underscores the broader concern about supply chain resilience in the pharmaceutical sector.

• Diversify Supplier Base: Engage with multiple API and KSM suppliers across different geographies to reduce dependency on a single source.

• Enhance Domestic Production: Invest in domestic manufacturing capabilities for both APIs and KSMs to build a more resilient supply chain.

• Strengthen Regulatory Compliance: Ensure adherence to international quality standards to prevent regulatory actions that could disrupt supply.

• Develop Contingency Plans: Establish robust contingency plans to address potential geopolitical or logistical disruptions, including alternative shipping routes and inventory management strategies.

• Monitor Regulatory Guidance: Stay informed about regulatory updates from agencies like the FDA and EMA to proactively address potential supply chain issues.

RISK_LEVEL: HIGH